These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8585836)

  • 1. [Neurobiology of parkinsonism. II. Experimental models].
    Ponzoni S; Garcia-Cairasco N
    Arq Neuropsiquiatr; 1995 Sep; 53(3-B):711-7. PubMed ID: 8585836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurobiology of parkinsonism. I. Neural substrates an neurochemistry of the basal ganglia].
    Ponzoni S; Garcia-Cairasco N
    Arq Neuropsiquiatr; 1995 Sep; 53(3-B):706-10. PubMed ID: 8585835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental models of Parkinson's disease].
    Féger J; Pessigliore M; François C; Tremblay L; Hirsch E
    Ann Pharm Fr; 2002 Jan; 60(1):3-21. PubMed ID: 11976545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experimental models, of Parkinson disease].
    Luquin MR
    Rev Neurol; 2000 Jul 1-15; 31(1):60-6. PubMed ID: 10948587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
    Rolland AS; Herrero MT; Garcia-Martinez V; Ruberg M; Hirsch EC; François C
    Brain; 2007 Jan; 130(Pt 1):265-75. PubMed ID: 17148469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The basal ganglia circuits, dopamine, and ambiguous word processing: a neurobiological account of priming studies in Parkinson's disease.
    Chenery HJ; Angwin AJ; Copland DA
    J Int Neuropsychol Soc; 2008 May; 14(3):351-64. PubMed ID: 18419834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Iancu R; Mohapel P; Brundin P; Paul G
    Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Of mice and men: more neurobiology in dementia.
    Codita A; Winblad B; Mohammed AH
    Curr Opin Psychiatry; 2006 Nov; 19(6):555-63. PubMed ID: 17012931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental models of Parkinson's disease: insights from many models.
    Tolwani RJ; Jakowec MW; Petzinger GM; Green S; Waggie K
    Lab Anim Sci; 1999 Aug; 49(4):363-71. PubMed ID: 10480640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
    Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
    Jakowec MW; Petzinger GM
    Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of the basal ganglia and movement disorders: from animal models to human clinical applications.
    Israel Z; Bergman H
    Neurosci Biobehav Rev; 2008; 32(3):367-77. PubMed ID: 17949812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
    Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
    Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of motor disorders in animal models of Parkinson's disease].
    Campos-Romo A
    Rev Neurol; 2008 Feb 1-15; 46(3):167-74. PubMed ID: 18297625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
    Goldstein DS; Li ST; Holmes C; Bankiewicz K
    J Pharmacol Exp Ther; 2003 Sep; 306(3):855-60. PubMed ID: 12805479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modelling synucleinopathies in genetically modified animals--successes and failures].
    Ninkina NN; Ustiugov AA; Bukhman VL
    Mol Biol (Mosk); 2008; 42(5):840-55. PubMed ID: 18988533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marmoset monkey models of Parkinson's disease: which model, when and why?
    Eslamboli A
    Brain Res Bull; 2005 Dec; 68(3):140-9. PubMed ID: 16325013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
    Blume SR; Cass DK; Tseng KY
    Exp Neurol; 2009 Sep; 219(1):208-11. PubMed ID: 19460369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.